SCHEMBL16474693

SCHEMBL16474693

COc1ccc(-c2ccc(=O)n(-c3ccccc3Cl)c2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
NPBWR1 P48145 2/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
BRD4 O60885 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 2/20 0.40
CNR1 P21554 2/20 0.40
CNR2 P34972 1/20 0.40
PKM P14618 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MAOB P27338 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16474685 0.85 IDH1 (0.49) SMN1; SMN2ALDH1A1KDM4EMAPK11MAPK14
SCHEMBL16474695 0.83 ALDH1A1 (0.42) KMT2AMEN1BRD4SMN1; SMN2ALDH1A1
SCHEMBL16474674 0.81 G6PD (0.40) SMN1; SMN2ALDH1A1KDM4EMAPK11MAPK14
SCHEMBL10079104 0.79 KDM4E (0.53) KMT2AMEN1BRD4SMN1; SMN2ALDH1A1
SCHEMBL10059808 0.78 MAPT (0.51) NPBWR1KMT2AMEN1BRD4SMN1; SMN2
SCHEMBL16474688 0.77 MEN1 (0.47) KMT2AMEN1BRD4ALDH1A1GAA
SCHEMBL16474686 0.77 MAPT (0.52) PTGS1PTGS2NPBWR1KMT2AMEN1
SCHEMBL16474705 0.75 PGR (0.42) KMT2AMEN1SMN1; SMN2ALDH1A1GAA
SCHEMBL10059782 0.75 ALDH1A1 (0.49) KMT2AMEN1ALDH1A1GAA
SCHEMBL5433228 0.74 MEN1 (0.54) NPBWR1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-9675593-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2017-06-13 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2017-05-04 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2016-09-15 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
US-9359379-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2016-06-07 US disclosed
WO-2015153683-A1 ANTI-FIBROTIC PYRIDINONES INTERMUNE, INC. (US) 2015-10-08 WO disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2014-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-20140107110-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-20160263090-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-20170121345-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 PTGS1 90/4885PTGS2 167/4885NPBWR1 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.